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Introduction
Multiparametric magnetic resonance imaging (mpMRI) 
of the prostate is revolutionizing the diagnosis of prostate 
cancer by providing high quality images with excellent 
tissue contrast. Historically, prostate MRI was available in 
only a few academic sites due to its high dependence on 
technical expertise and radiologist experience, but in recent 
years significant advances in hardware and software have 
greatly simplified image acquisition, leading to a steady 
improvement in the quality and diagnostic performance of 
MRI scans. Furthermore, the Prostate Imaging-Reporting 
and Data System (PI-RADS) version 2 has been recently 
introduced, establishing the minimum technical parameters 
that should be utilized, standardizing terminology, and 
providing guidelines for interpretation and reporting 
of imaging findings. These advances have allowed the 
clinical applications to broaden from loco-regional staging 
of prostate cancer to tumor detection, localization, risk 
stratification, and image-guided biopsy and treatment. The 
purpose of this article is to introduce the basic concepts of 
mpMRI of the prostate and its clinical applications, which 
will be covered in detail in subsequent chapters of this issue. 
Hardware
MRI is dependent on strong magnetic fields and the 
electromagnetic properties of hydrogen to generate the 
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signal that is used to create images. The signal is very weak, 
though, and the main advantage of a 3 Tesla (3T) versus 
a 1.5 Tesla (1.5T) scanner is the increased signal-to-noise 
ratio. The increased signal strength at 3T allows for faster 
acquisition of images with higher spatial and temporal 
resolution. 3T scanners are also able to acquire other high 
demand sequences that may provide additional diagnostic 
information such as refined pharmacokinetic data (1). 
Though these sequences may be obtained on 1.5T scanners, 
the decreased signal to noise ratio, and lower spatial and 
temporal resolution provide suboptimal image quality. A 
growing number of studies are showing improved image 
quality resulting in better detection and characterization 
of prostate cancer with higher field strength (2). While 
there are many advantages when compared to 1.5T 
scanners, higher strength magnets are also more sensitive 
to inhomogeneous magnetic fields; and this can exacerbate 
artifacts cause by metallic hardware, such as hip prostheses, 
or air and stool in the rectum. 
All prostate MRI exams use an external phased array coil 
placed over the pelvis to excite the protons and receive their 
signal to generate the images; however some institutions 
elect to use an additional endorectal coil. These coils 
are positioned directly opposed to the prostate, further 
increasing the signal and resolution. The use of endorectal 
coils is debatable for both 1.5T and 3T scanners, but 
generally considered a requirement for 1.5T systems.
Recent studies have shown that the use of an endorectal 
coil does not increase tumor detection, but the ability to 
obtain higher resolution images may improve local staging. 
While the endorectal coil improves image quality, it comes 
with some disadvantages including patient discomfort, gland 
deformation and enema preparation. Ongoing hardware and 
software improvements may lead to adequate and accurate 
imaging without it. 
Sequences
Applying magnetic gradients and radiofrequency pulses 
generates MR images. By changing scanning parameters 
one obtains different pulse sequences, or sequences for 
short. Each sequence provides different, but complementary 
information which is crucial for diagnosis. A mpMRI exam 
of the prostate consists of several sequences including 
T1-weighted, T2-weighted, dynamic contrast-enhanced, 
and diffusion-weighted MRI (Figure 1). Occasionally, 
MR spectroscopic imaging is also obtained. Each of 
these sequences can be thought of distinct components 
that together comprise a complete MR examination. A 
basic knowledge of tissue signal characteristics with each 
sequence is key for understanding prostate MRI. A finding 
seen on any single sequence should always be correlated 
with the other sequences for accurate characterization.
T2-weighted MR imaging
T2-weighted images (T2WI) are the mainstay of prostate 
MRI. High resolution T2WI are acquired in three different 
imaging planes (axial, coronal, and sagittal) with a small 
field-of-view focused on the prostate. These images 
provide the best opportunity to evaluate the prostatic zonal 
anatomy and to determine the presence of extra-prostatic 
extension. Findings of extraprostatic extension (EPE) 
include asymmetry of neurovascular bundles, obliteration of 
rectoprostatic angle, bulging of the prostatic contour, and 
capsular irregularity with tumor in the rectoprostatic fat 
(Figure 2). 
A recent meta-analysis by de Rooij et al. showed 53% 
sensitivity, 91% specificity for detection of EPE (3). The 
modest sensitivity has caused some to argue against the use 
of MRI, but the accuracy and sensitivity have been shown 
to improve when patients are scanned on 3T systems and 
images reviewed by experienced readers (3,4).
In the peripheral zone, typical prostate cancers appear 
as round or ill-defined dark (low T2 signal) lesions on a 
bright (high T2 signal) background of glandular tissue. 
Unfortunately low T2 signal in the peripheral zone is 
nonspecific; prostatitis, post-biopsy hemorrhage, glandular 
atrophy, and post-treatment changes can have a similar 
appearance. Accordingly, T2WI alone is not adequate for 
the diagnosis and localization of prostate cancer; in one 
study, Rosenkrantz et al. demonstrated a diagnostic accuracy 
of 60% (5). This underscores the importance of correlation 
with clinical history as well as imaging characteristics on the 
remaining sequences (6).
The transition zone contains variable amounts of 
glandular (high T2 signal), and stromal (low T2 signal) 
tissue. Since prostate cancer usually demonstrate low 
T2 signal, benign stromal tissue can mimic or obscure 
malignant lesions. Transition zone tumors are difficult 
to detect, yet T2WI is the preferred imaging sequence 
for evaluation of such lesions because there is significant 
overlap of imaging findings of benign prostatic hyperplasia 
and prostate cancer on the other sequences (7). Hoeks 
et al. recently compared the accuracy of T2WI alone with 
mpMRI and did not find a difference between the two 
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(68% vs. 66%) (8). The diagnostic accuracy of T2WI for 
the detection of transition zone tumors ranges from 62% to 
81% (9-11).
T1-weighted MR imaging
T1 weighted images (T1WI) are not utilized for the direct 
assessment of prostate cancer, as the zonal anatomy and 
tumors are very poorly visualized. However, these images 
are usually acquired using a large field of view of the pelvis, 
allowing for the assessment for regional lymph nodes and 
osseous structures. While an abdomen and pelvis CT scan 
and bone scintigraphy are often obtained in high-risk cases, 
this sequence provides an opportunity to detect unsuspected 
metastases.
T1WI are also valuable for detection of post-biopsy 
hemorrhage. Hemorrhage may mimic tumor on T2WI 
because it has low T2 signal, but it is easy recognized on 
T1WI (Figure 3). Furthermore, hemorrhage may also limit 
the accuracy of other sequences. There is no consensus as to 
the time interval between prostate biopsy and mpMRI, but 
the American College of Radiology and European Society 
of Urogenital Radiology suggest at least 6 weeks.
Diffusion-weighted MR imaging (DWI)
DWI generates image contrast based on differences in the 
rate of diffusion of water molecules in soft tissues relative to 
free solution. With an increase in grade of prostate cancer, 
there is an increase in cellularity, progressive loss of ductal 
architecture, and decrease the cytoplasm-to-nucleus ratio, 
all of which reduce the ability of water to diffuse. In other 
Figure 1 Normal prostate anatomy. Axial T2WI (A), DWI (B), ADC map (C), and MRSI (D) at the midlgand to apex of a normal prostate 
of a young man. The peripheral zone (PZ) comprises more than 70% of the prostate volume. Little tissue is seen in the transition zone (yellow 
arrow). There is uniform distension of the rectum due to endorectal coil (ERC). MRSI (D) demonstrates normal choline + creatinine-
to-citrate and choline-to-citrate ratios. T2WI, T2-weighted image; DWI, Diffusion-weighted MR imaging; ADC, apparent diffusion 
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Figure 2 Axial T2WI, DWI, ADC map, and DCE at the midgland to base of the prostate of a 64-year-old man with biopsy proven prostate 
cancer (Gleason score 5+5). There is a large area of low T2 signal in the peripheral and transition zones, right greater than left side (2A, *). 
Extraprostatic extension (EPE) is present (arrow), as tumor is noted beyond the boundaries of the prostate. Seminal vesicle invasion is also 
present bilaterally (not shown). DWI demonstrates increased signal (2B, asterisk), which is confirmed with low values on the ADC map (2C, *). 
DCE demonstrates rapid contrast uptake at the region of low signal on T2WI and ADC map (2D, *). T2WI, T2-weighted image; DWI, 
diffusion-weighted MR imaging; ADC, apparent diffusion coefficient; DCE, dynamic contrast-enhanced.
words, prostate cancer demonstrates restricted diffusion 
(of water molecules) and the higher the grade of cancer, 
the more significant is the restriction (Figure 2). DWI 
is comprised of two sets of images for analysis, the high 
b-value images and an apparent diffusion coefficient (ADC) 
map. A b-value is a parameter of DWI that measures the 
strength of the diffusion weighting. Several studies have 
shown improved tumor detection using high b-values in 
the range of 1,400–2,000 (12-15). While the interpretation 
of DWI is subjective, the restriction of water molecules 
can be quantified. This is done generating ADC maps 
and measuring ADC values (mm2/s). Structures that 
demonstrate reduced diffusion will appear bright on DWI 
and dark on the ADC map (low ADC values) (Figure 2). 
Several studies have shown an inverse correlation between 
ADC values and Gleason score (16-18). In addition, 
DWI and ADC maps are very useful for detection of 
prostate cancer, particularly in the peripheral zone, with 
sensitivities ranging from 65% to 84%, and specificities of 
77% to 87% (9,19).
 
Dynamic contrast-enhanced (DCE) MR imaging
DCE MRI is performed by obtaining T1-weighted images 
with suppression of the signal of fat before and after the 
administration of intravenous gadolium based contrast 
agents. Post contrast images of the entire gland are acquired 
in rapid succession over several minutes, allowing for 
the study of the kinetics of contrast enhancement in the 
prostatic tissue. An entire set of images is typically acquired 
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every 5–10 seconds for at least 2 minutes (Figure 2).
Ma l ignant  ce l l s  r e l ea se  f ac tor s  tha t  promote 
neovascularization and increased capillary permeability. 
These factors are believed to cause prostate cancer to 
demonstrate rapid enhancement and faster washout of 
contrast relative to normal tissue. While many tumors 
demonstrate these classic features, kinetics are variable 
and DCE alone cannot definitively diagnose or exclude 
malignancy. This determination must be made in conjunction 
with the morphologic and functional features seen on the 
accompanying sequences. If abnormal enhancement is seen, 
other sequences must be closely examined to confirm the 
presence or absence of a suspicious lesion.
While PI-RADS version 2 still recommends the 
acquisition of DCE, its use remains a matter of debate. 
While multiple studies have shown limited additional 
benefit beyond T2-weighted and diffusion-weighted 
(5,8,20), others have suggested that DCE is helpful for the 
detection of small lesions and to predict treatment response. 
There are three different methods for interpretation of 
DCE images: subjectively using visual inspection, semi-
objectively using calculation of various kinetic parameters, 
enhancement curves and colorized parametric maps 
superimposed on anatomic images, or objectively using 
pharmacokinetic models that measure concentration of 
gadolinium within the tissues (21).
MR spectroscopic imaging (MRSI)
Proton MRSI depicts the metabolic profile of tissues. 
Figure 3 Axial T1WI (A) through the midgland of the prostate demonstrates a region of increased T1 signal in the right peripheral zone 
(arrow). On T2WI (B), this area has low signal intensity (B, arrow). This combination of high T1 and low T2 signal intensities is compatible 
with post biopsy hemorrhage. Note a second focus of low T2 signal intensity in the left peripheral zone (B, *). This second focus has low 
signal intensity on T1WI (A, *) and is, therefore, suspicious for prostate cancer. The likelihood of prostate cancer is further increased based 
on the results of DWI and ADC map, as the lesion demonstrates high signal on DWI (C, *) and low signal on ADC map (D, *). There is no 
reduced diffusion within the region of hemorrhage (C, arrow). T1WI, T1 weighted image; T2WI, T2-weighted image; DWI, diffusion-
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In the case of prostate cancer, three metabolites are of 
main interest: citrate, choline, and creatine. Citrate is 
found in abundance in normal prostatic tissue, but it is 
decreased when the gland is replaced by cancer. Choline is 
a phospholipid membrane component and it is increased in 
cancer because of high cell membrane turnover associated 
with neoplastic proliferation. Creatine is also a normal 
peak, but it remains unchanged in the presence of cancer 
and serves as internal reference. Relative concentrations of 
these metabolites are quantified using choline + creatinine-
to-citrate and choline-to-citrate ratios. Use of MRSI 
remains limited to a few institutions, as image acquisition 
is difficult, extensive post-processing is required, and 
interpretation is time consuming and challenging. 
Although studies from experienced institution have found 
promising results (22,23), other recent research failed to 
show additional benefit, perhaps because of the challenges 
mentioned above (24,25). 
Patient preparation
The high magnetic field MRI scanners (1.5T and 3T) 
used in clinical practice generally have bore sizes of 
approximately 60 cm. The confined space and prolonged 
image acquisition can cause anxiety even when patients do 
not suffer from claustrophobia. It is therefore important 
to alert patients to this possibility and thoroughly explain 
the procedure. If necessary, high quality images may still 
be obtained with the aid of anxiolytic medications. Yet, 
these are usually not available in radiology departments, 
and must be prescribed by the referring physicians in 
advance. In addition to the standard screening procedures 
that all patients undergoing MRI must partake in (Figure 4), 
there are certain aspects of prostate MRI that require 
additional consideration. There are no formal guidelines 
for patient preparation and procedures vary from practice 
to practice. Some centers utilize antispasmodic agents such 
as butylscopolamine prior to image acquisition in order to 
decrease peristalsis and motion related artifacts, though 
use of these agents is controversial, as studies have failed 
to demonstrate improved image quality (26). Though not 
required, patients being imaged with an endorectal coil are 
advised to use a saline laxative enema within 3 hours of the 
examination in order to facilitate coil placement as well as 
reduce artifacts created by air and stool (27) (Figure 5). 
Patients are generally scanned in the supine position as 
this is better tolerated and minimizes respiratory motion. 
One of the main indications for scanning a patient in the 
prone position is the presence of a large quantity of rectal 
gas in cases in which an endorectal coil is not being used. 
This change in positioning can promote redistribution of 
bowel gas, decreasing the probability of artifact, thereby 
producing higher quality images.
Clinical applications
The most widely accepted uses of mpMRI of the prostate 
include biopsy guidance, local staging, post-treatment 
assessment, and as an adjunct tool for active surveillance (AS).
Biopsy
For many years, the standard for prostate biopsy was the 
sextant technique of sampling 6 separates sites, which 
over time has expanded up to 30 sites. The limitations of 
such systematic, non-targeted techniques are now well 
recognized, but in short they are associated with over 
diagnosis of low-grade disease and under diagnosis of 
clinically significant disease, with discrepant Gleason scores 
between biopsy and surgical specimens (28). The superior 
tissue contrast and improved visualization of prostate cancer 
using mpMRI has led to the implementation of targeted 
biopsy. Targeted biopsy techniques include cognitive fusion 
biopsy, i.e., visual co-registration of MRI and TRUS, 
MRI/TRUS fusion biopsy, where MRI data is overlaid to 
real-time TRUS images, and in-bore MRI guided biopsy, 
when biopsies are performed with the patient inside the 
MRI scanner. Cognitive fusion has been shown to improve 
disease characterization when compared to systematic 
biopsy (29), and both MRI/TRUS fusion and in-bore 
techniques are better than the cognitive and systematic 
approaches (30,31). These newer MRI-guided procedures 
reduce sampling error and detect more high-risk and fewer 
low-risk cancers when compared to systematic biopsy 
(31,32). It is important to understand that though these 
techniques are an improvement over the prior standard 
of care, up to 17% of clinically significant cancers are still 
missed when compared to prostatectomy specimens (33,34). 
For this reason, the current recommendation is to perform 
systematic biopsy in addition to targeted biopsy (35). In 
addition to directing biopsy, improved tumor localization 
and characterization can also guide focal therapy 
such as ablation (cryotherapy, laser, photodynamic), 
electroporation, and high intensity focused ultrasound. 
Targeted biopsy methods will be discussed in further 
detail later in this issue. 
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Figure 4 MRI screening form. MRI, magnetic resonance imaging.
Local staging
mpMRI of the prostate is currently the best option for local 
staging. The limitations of serum PSA and digital rectal 
examination for staging are well recognized. And while the 
accuracy of transrectal ultrasound (TRUS) for the detection 
of EPE can be similar to that of T2WI when performed by 
an experienced operator (36), it typically does not provide 
detailed enough evaluation for accurate staging.
A recent meta-analysis showed high specificity for the 
detection of EPE, seminal vesicle invasion (SVI), and overall 
staging of T3 disease when using T2WI with DWI or DCE to 
range from 88–96% (3). mpMRI may also be helpful for local 
lymph node staging and evaluation of pelvic osseous metastases, 
but given the limited field-of-view, other cross sectional imaging 
modalities, such as computed tomography (CT) and nuclear 
medicine techniques, are better suited for these tasks . 
Post-treatment evaluation
A rising PSA following definitive therapy, i.e., biochemical 
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Figure 5 Examples of the effects of susceptibility artifact on axial T2WI and DWI. In Figure 5A, an endorectal coil (ERC) is in place. 
However, adjacent to the coil, there is a small volume of colonic gas—a crescentic area of low signal external to the coil (arrow)—that results 
in distortion of the prostate on DWI (B). Metallic objects may also cause susceptibility. The presence of multiple permanent prostatic 
implants of brachytherapy (PPI) and hip prostheses (H) can cause susceptibility artifact that limits evaluation on T2WI (C,E), however the 
DWI sequence is more sensitive to this artifact and rendered non-diagnostic (D,F). T2WI, T2-weighted image; DWI, diffusion-weighted 
MR imaging.
failure, provides accurate evidence of recurrent prostate 
cancer. The challenge is determining whether this increase 
in PSA is a result of isolated local recurrence or metastatic 
disease.
mpMRI has high sensitivity and specificity for detection 
of local recurrence ranging from 85–97% and 90–100%, 
respectively (37). Different sequences may be of particular 
value in different situations. For example a recent study 
showed the increased sensitivity of DWI for detection of 
local recurrence following radiation therapy (23), while 
other studies have shown that DCE is the most sensitive 
for diagnosis of local recurrence following prostatectomy 
(38,39). As for patients who are treatment-naïve, imaging 
findings are utilized to guide biopsies in this group of men. 
While the detection of local recurrence does not exclude 
the presence of metastatic disease, a negative mpMRI 
will increase its probability. Other imaging modalities, 
such as CT, nuclear scintigraphy, and positron emission 
tomography are usually used to evaluate for distant 
metastases. 
AS
One of the main challenges of AS is accurate selection 
of patients with prostate cancer that will never become 
clinically manifest and exclusion of men whose cancers 
should be treated with definitive therapy. Several studies 
have shown that up to about 40% of patients under AS 
receive definitive treatment within 3–5 years, typically 
because re-biopsy diagnoses disease upgrading (40-42). 
Disease upgrade, however, may be due to inaccurate 
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of disease. Given the high quality anatomic and functional 
data provided by mpMRI, some have suggested mpMRI as a 
potential adjunct to AS, first by more accurately identifying 
candidates for surveillance, and also by monitoring men 
classified as low risk patients (33,43,44). For example, a 
study by Thompson et al. showed mpMRI to have high 
sensitivity and negative predictive value for clinically 
significant prostate cancer (45). In addition, many AS 
patients opt for definitive therapy to avoid repeat routine 
biopsies, which in some protocols are performed yearly. 




Multiparametric MRI of the prostate is an exam consisting 
of several components including T2-weighted imaging, 
T1-weighted imaging, diffusion-weighted imaging, and 
dynamic contrast enhanced imaging. It provides high quality 
anatomic and functional images that improve the diagnosis 
of prostate cancer, assisting with risk-stratification and 
treatment selection. The concepts presented in this article 
are important for providing a foundation of knowledge that 
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